Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
lol people you recommended NWBO to are now your park bench neighbor and refuse to talk to you?
Joan Lappin's articles in the past did have an enormous impact on the SP taking it from 1.45 to over 1.80. That impact has probably subsided now since everyone knows it does not last and what she predicted came not into fruition in the timeframe she predicted it would.
its not very difficult to guess why this is taking so absurd long, SOS takes a good stab at it
https://smithonstocks.com/northwest-biotherapeutics-fda-statement-regarding-use-of-external-controls-in-clinical-trials-is-a-huge-positive/
exactly thanks Flex
I have not misused anyone's email give me a break.
Hey Flex and thank you good morning to you too
You are right its up to the registered author to delete an account with NREJM. My mistake
You may delete your account at any time by logging into your account and choosing the “delete my account” link on the User ID/Password page.
It's also been stated that the lead author should be LL.
The NEJM Author Center provides an array of informational resources to help guide you through the manuscript submission, review, and publication process. Learn about:
Editorial policies
Rigorous editorial, peer, and statistical review processes
How to prepare new and revised manuscripts for submission
What to expect if NEJM publishes your manuscript, including promotion and generous author permissions for content reuse
1) Has Dr. Bosch submitted previous articles to NEJM, or would this be his first.
thanks
but a little too many holes for it to imply an impending article
I will guess no publication in the NEJM in H1 2022 despite this great find by dennis that Dr B submitted it.'
Look,
I personally dont think that https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-018-1507-6
was offered to NEJM by Liau, Ashkan and Bosch before for the simple reason that NEJM is not particularly fond of publishing interim blinded trials.
Bosch only published 4 times before https://www.biomedcentral.com/search?query=author%23%22Marnix%20L.+Bosch%22 none of them were in NEJM
I cant rule out the account was created prior to submitting the DCVAX L article but I hardly doubt it. So there is no guarantee as with many many posts here as have your posts no guarantee.
Also, Dr Liau probably submitted the article. But the NEJM author-center offers the option to assign co-authors to work on the article together and after. I think that is what happened here.
This is past absurd. If Dr B wants to read the NEJM online he would have to register his email account.
For transferring manuscripts:
If your manuscript is rejected for publication by NEJM and you elect to have NEJM transfer your manuscript to another listed journal, we will transfer your submitted manuscript and related files (including external peer reviewer comments for authors), your and your coauthors’ names and contact information, and a copy of the rejection letter you receive from us.
with his NWBO email thus under an NWBO account?
Could be to submit what?
There is of course no reason why Dr B would ever have registered with the NEJM in the past.
I suspect all three (Ashkin, LL, and Bosch) have an account and work on it simultaneously
I haven't gotten around that to do so, but here is the problem in that thesis. LL has submitted in NEJM before so that would not prove it's for the one we are all waiting for? with MB I don't have that problem
by all means go ahead
I wanted to find out if NWBO had indeed submitted a manuscript with NEJM for sure. Then I thought of a simple plan to determine this. I visited The NEJM Author Center where authors can register to submit manuscripts with NEJM which can be found here:
https://www.nejm.org/author-center/home
Welcome. Thank you for considering the New England Journal of Medicine (NEJM) for your manuscript.
The NEJM Author Center provides an array of informational resources to help guide you through the manuscript submission, review, and publication process. Learn about:
Editorial policies
Rigorous editorial, peer, and statistical review processes
How to prepare new and revised manuscripts for submission
What to expect if NEJM publishes your manuscript, including promotion and generous author permissions for content reuse
NEJM ONLINE SUBMISSION
The primary email address you entered is linked to an existing account.
I have zero hopes of BLA already being submitted. Hell if anything I would over the moon happy with just TLD at this point.
I think this whole talk about BLA is silly as long as we have not seen TLD ( and a publication)
But yes it would be an incredible waste of time if NWBO had not worked on a BLA
that is also true.
NWBO would be a world-first where BLA submission would proceed TLD announcement
I think its highly unlikely but I hope Im wrong
yes I agree
I got the same reply
DD this is how I see it what happened
Scenario 1
1. We know that the conference presentation was never meant to be held prior to TLD + Publication so during the quiet time.
=> Bosch must have been receiving many emails from the conference months prior and right up till the conference. So the conference and his responsibility for his attendance must have been on his mind all that time. Therefore if he knew weeks before the start of the conference that TLD + Publication would take a long time he would have canceled weeks before.
2. On Monday, January 10 MB was made aware by either email or a phone call from the event manager that his time of appearance had been shifted for Jan 20 from 11..40 to 12.10.
Please contact your Event Manager or Program Director for more information. Please note that all times and dates are subject to changes, so please be aware of any updates that may be communicated from your Program Director
What is the deadline to provide for my presentation All presentations are required a week before the meeting. Reminders and deadlines will be sent to you by email by your Event Manager and Program Director
In response to your enquiry, I’m sorry to confirm but Marnix Bosch will no longer be presenting at this year’s event. I apologise, he has had to drop out last minute. Kind regards, Kiran Thomson
you are probably right. Im going to do a bit more research and think this over
thanks for all your great research DD
One thing Im convinced about the conference was supposed to be after results had been disclosed. There is just no way NWBO will present anything in their quiet period. I think it was kinda not on MB's radar when he got the email Thursday, got reminded, and canceled.
MB is definitely a co-author as he was in May 2018.
That to me indicates and I'm speculation now I realize that, that they still have not a definite publication date. Could be peer-reviewing which I suspect could be the last details.. we don't know where they are .
mmmmmm
https://glioblastoma-drugdevelopment.com/virtual-event-faqs/#speaker
when am I speaking
Please contact your Event Manager or Program Director for more information. Please note that all times and dates are subject to changes, so please be aware of any updates that may be communicated from your Program Director
What is the deadline to provide for my presentation
All presentations are required a week before the meeting. Reminders and deadlines will be sent to you by email by your Event Manager and Program Director
So taking Dr. Bosch out of the conference in order to get this to the finish line, would almost certainly mean they need him working on finishing up the Journal preparation (Aka: back and forth editing), imo.
at what point will NWBO get a name for constantly pulling out of conferences? Seriously. This must be a huge nuisance to the glioblastoma-drugdevelopment conference organization they pulled out 4 days before it started, people are paying admittance.
ooh yeah, it happens that people forget its the other way around.
The same for crypto as in Casinos always place your money on the color or number where the ball will fall on next, people seem to forget that simple rule lol
Are you really saying the FDA regulates the ability for NWBO to sell DCVax-L in the UK?
For pharmaceutical companies operating in the United States, the U.S. Food and Drug Administration (FDA) regulates the drug approval process and oversees the expanded access pathway for patients with an unmet medical need to access investigational drugs under 21CFR 312 Subpart 1.
However, pharma companies seeking access to the European market face dealing with the European Medicines Agency (EMA) for drug approvals, as well as navigating a myriad of country-specific regulations on accessing investigational drugs.
wrong
NWBO needs continuous FDA permission to sell DCVAX L as compassionate treatment, which we know for a few days now is exactly what they are doing, has just started up, in Sawston. FDA has seen the data for sure, combine the two and you know what time it is.
that is correct
Moreover, the FDA and the MHRA have permitted the continuation of the compassionate sales of DCVAX L in Sawston after the FDA has become aware of the unblinded data. It would be beyond bizarre if in the near future the FDA would turn around and disapprove DCVAXL after the BLA is submitted.
P.S.: In "Wall Streat", when Sheen whispered "Blue Horseshoe loves Anacott Steel.", he could not talk loudly because they were in a quite period.
It's my impression that when the first Dc Vax L vaccine is made at Sawston, that event will be considered by nwbo's DC law firm to be a material event.Then it will be 8-K ed and maybe PRed
you can only say that you are glad that you didnt invest all after topline data+publication or am I wrong?
Basically he got a vague response that could have been used a year ago as easily as now. It could cover just about any more specific reason and so tells us next to nothing, which is par for the course.
Your explanation makes sense. If the presentation was always intended prior to TLD / journal as we have seen Dr Liau's last year then they would have not canceled. Something very short notice came up so they had to cancel and if I had to guess it is NEJM letting NWBO know they had to move the publication to another time frame.